



Relburn-Metabolomics, Inc.
Westfield, NJ 07090

Relburn-Metabolomics to Outline Research Progress at BIO Investor Forum

Westfield, NJ – October 20, 2015 -- Relburn-Metabolomics, Inc. announced that the Company has been selected to present at the annual BIO Investor Forum taking place in San Francisco from October 20-21, 2015. BIO is the industry's premier organization focused on life science innovations. The Forum routinely attracts key executives and venture investors with extensive experience in biotechnology and pharmaceuticals.

Relburn is an emerging life-science company focused on improving health for patients with metabolic and inflammatory diseases. During the Company's presentation, Dr. Raymond P. Warrell, Jr., Chief Executive Officer, will provide an update of the Company's scientific, business and development activities, and will meet with potential investors and partners. Presentation information follows:

Event:	BIO-Investor Forum
Date:	Wednesday October 21, 2015
Time:	9:30 AM (Pacific Time)
Location:	Hilton Parc 55 Hotel
Room:	Balboa

About Relburn-Metabolomics

Relburn's lead program is focused on the development of transformational therapy for chronic gout – a disease whose prevalence is doubling every 10 years and currently afflicts 16 million subjects in major markets. Gout is caused by excess uric acid (UA) in blood and connective tissues that leads to exquisitely painful and destructive arthritis, kidney failure, and possibly accelerated cardiovascular disease. Standard treatment seeks to either reduce production or increase excretion of UA. Unlike other anti-gout drugs, Relburn compounds exert bifunctional activities on *both* UA production *and* excretion. Targeting enzymes that mediate these activities, Relburn compounds are markedly more potent than standard drugs and have demonstrated exceptional clinical activity.

Gout treatment is focused on reducing UA to a target serum level less than 6.0 mg/dL that is known to be beneficial. The Relburn prototype drug – tested in more than 350 patients -- showed that serum UA routinely dropped to less than 1.0 mg/dL, even at low

doses. With this “clinical proof-of-concept”, Relburn has synthesized compounds to further enhance clinical activity and reduce potential side-effects. This drug library is covered by patent applications that are exclusively owned by the Company. Relburn believes its drugs may replace current 1st-line treatments for gout, thereby leading to meaningful improvement in patient well-being.

Further information about Relburn-Metabolomics, Inc. can be accessed at: www.relburn.com.

About BIO Investor Forum

More information about the meeting can be accessed at: <https://www.bio.org/events/conferences/14th-annual-bio-investor-forum>

This press release may contain forward-looking statements with respect to business conducted by Relburn-Metabolomics, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets, or future developments, and are not statements of historical fact. The words “potentially”, “anticipates”, “believes”, “expects”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements, and there are a number of factors that could cause actual results and developments to differ materially.

Relburn company information: info@relburn.com

SOURCE: Relburn-Metabolomics[®] Inc.